UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Thirty-to-forty percent of patients with primary biliary cholangitis inadequately respond to ursodeoxycholic acid. Our aim was to assemble national, real-world data on the effectiveness of obeticholic acid (OCA) as a second-line treatment, alongside non-licensed therapy with fibric acid derivatives (bezafibrate or fenofibrate). METHODS: This was a nationwide observational cohort study conducted from August 2017 until June 2021. RESULTS: We accrued data from 457 patients; 349 treated with OCA and 108 with fibric acid derivatives. At baseline/pre-treatment, individuals in the OCA group manifest higher risk features compared with those taking fibric acid derivatives, evidenced by more elevated alkaline phosphatase values, and a larger proportion of individuals with cirrhosis, abnormal bilirubin, prior non-response to ursodeoxycholic acid, and elastography readings >9.6kPa (P < .05 for all). Overall, 259 patients (OCA) and 80 patients (fibric acid derivatives) completed 12 months of second-line therapy, yielding a dropout rate of 25.7% and 25.9%, respectively. At 12 months, the magnitude of alkaline phosphatase reduction was 29.5% and 56.7% in OCA and fibric acid groups (P < .001). Conversely, 55.9% and 36.4% of patients normalized serum alanine transaminase and bilirubin in the OCA group (P < .001). The proportion with normal alanine transaminase or bilirubin values in the fibric acid group was no different at 12 months compared with baseline. Twelve-month biochemical response rates were 70.6% with OCA and 80% under fibric acid treatment (P = .121). Response rates between treatment groups were no different on propensity-score matching or on sub-analysis of high-risk groups defined at baseline. CONCLUSION: Across the population of patients with primary biliary cholangitis in the United Kingdom, rates of biochemical response and drug discontinuation appear similar under fibric acid and OCA treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationA Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498
Self-citationLammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Self-citationCarbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386
Self-citationHirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Self-citationGhonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
Harms, M. H., van Buuren, H. R., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Hirschfield, G. M., Parés, A., Floreani, A., Mayo, M. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.001 · Cited by 289
Self-citationA randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology · doi:10.1002/hep.29569 · Cited by 281
Self-citation
Research works printed but not linked: 16
- Iwasaki, 1999, Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis, Hepatol Res, 16, 12, 10.1016/S1386-6346(99)00033-9 · DOI
- Corpechot, 2018, A placebo-controlled trial of bezafibrate in primary biliary cholangitis, N Engl J Med, 378, 2171, 10.1056/NEJMoa1714519 · DOI · Paper page
- Murillo Perez, 2020, Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase, Am J Gastroenterol, 115, 1066, 10.14309/ajg.0000000000000557 · DOI · Paper page
- Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI · Paper page
- Reig, 2021, Obeticholic acid and fibrates in primary biliary cholangitis: comparative effects in a multicentric observational study, Am J Gastroenterol, 116, 2250, 10.14309/ajg.0000000000001343 · DOI · Paper page
- Eaton, 2020, Liver injury in patients with cholestatic liver disease treated with obeticholic acid, Hepatology, 71, 1511, 10.1002/hep.31017 · DOI · Paper page
- Alrubaiy, 2019, PBC-10: a short quality of life measure for clinical screening in primary biliary cholangitis, Aliment Pharmacol Ther, 50, 1223, 10.1111/apt.15554 · DOI
- Hirschfield, 2018, The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines, Gut, 67, 1568, 10.1136/gutjnl-2017-315259 · DOI · Paper page
- 2017, Obeticholic acid for treating primary biliary cholangitis, Final Apprais Determ
- Corpechot, 2012, Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis, Hepatology, 56, 198, 10.1002/hep.25599 · DOI · Paper page
- Lammers, 2014, Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study, Gastroenterology, 147, 1338, 10.1053/j.gastro.2014.08.029 · DOI · Paper page
- Nevens, 2016, A placebo-controlled trial of obeticholic acid in primary biliary cholangitis, N Engl J Med, 375, 631, 10.1056/NEJMoa1509840 · DOI · Paper page
- Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI · Paper page
- Harms, 2019, Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis, J Hepatol, 71, 357, 10.1016/j.jhep.2019.04.001 · DOI · Paper page
- Carbone, 2018, Pre-treatment prediction of response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis: the UDCA Response Score, Lancet Gastroenterol Hepatol, 3, 626, 10.1016/S2468-1253(18)30163-8 · DOI · Paper page
- Ho, 2011, MatchIt: nonparametric preprocessing for parametric causal inference, J Stat Softw, 42, 1
Cited by
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000395 · Cited by 127
“The improvement in pruritus with seladelpar contrasts with obeticholic acid, a bile acid analog and FXR agonist that is conditionally approved as a secondline treatment for PBC, which can induce or worsen pruritus in a dose-dependent manner.[15,32,33] Seladelpar appeared safe and well tolerated, with no deaths or grad…”
BackgroundSelf-citationObeticholic Acid for Primary Biliary Cholangitis
Floreani, A., Gabbia, D., & De Martin, S. (2022) · Biomedicines · doi:10.3390/biomedicines10102464 · Cited by 41
Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17755 · Cited by 39
Self-citationPrimary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000864 · Cited by 38
Self-citationAmpuero, J., Lucena, A., Berenguer, M., Hernández-Guerra, M., Molina, E., Gómez-Camarero, J., Valdivia, C., Gómez, E., Casado, M., Álvarez-Navascuez, C., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000826 · Cited by 17
Metadata
- Authors
- Abbas, N., Culver, E. L., Thorburn, D., Halliday, N., Crothers, H., Dyson, J. K., Phaw, A., Aspinall, R., Khakoo, S. I., Kallis, Y., Smith, B., Patanwala, I., McCune, A., Chimakurthi, C. R., Hegade, V., Orrell, M., Jones, R., Mells, G., Thain, C., Thain, R.-M., Jones, D., Hirschfield, G., & Trivedi, P. J.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 21
- Issue
- 6
- Pages
- 1561-1570.e13
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W4291708356
- Cited by
- 39
- References
- 21
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis. https://app.cochat.ai/papers/10.1016/j.cgh.2022.07.038
- The paper
- Abbas, N., Culver, E. L., Thorburn, D., Halliday, N., Crothers, H., Dyson, J. K., Phaw, A., Aspinall, R., Khakoo, S. I., Kallis, Y., Smith, B., Patanwala, I., McCune, A., Chimakurthi, C. R., Hegade, V., Orrell, M., Jones, R., Mells, G., Thain, C., . . . Trivedi, P. J. (2023). UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2022.07.038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.